Navigation Links
EMAS publishes position statement about the post-reproductive health of women
Date:5/17/2011

Amsterdam, 17 May 2011 - Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society (EMAS) in the journal Maturitas (http://www.maturitas.org/) on managing menopausal women with a personal or family history of venous thromboembolism (VTE). The statement includes summary recommendations as a quick aid for the busy clinician.

"The expanding ageing female population means that clinicians increasingly have to deal with post-reproductive health problems," said Professor Serge Rozenberg, President of EMAS. "EMAS has risen to the challenge and is providing clear guidance on the position statements covering hormone and non hormone therapy (HT) options, as well as complementary and alternative therapies."

The statement will be published in the June 2011 issue:

Venous thromboembolism, including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a serious cardiovascular event whose incidence rises with increasing age. Randomized controlled trials have shown an increased risk of VTE in oral hormone therapy (HT) users. There are no randomized trial data on the effect of transdermal estrogen on VTE. Recent observational studies and meta-analyses suggest that transdermal estrogen does not increase VTE risk. These clinical observations are supported by experimental data showing that transdermal estrogen has a minimal effect on hepatic metabolism of hemostatic proteins as the portal circulation is bypassed.

A personal or family history of VTE, especially in individuals with a prothrombotic mutation, is a strong contraindication to oral HT but transdermal estrogen can be considered after careful individual evaluation of the benefits and risks. Transdermal estrogen should be also the first choice in overweight/obese women requiring HT. Observational studies suggest that micronized progesterone and dydrogesterone might have a better risk profile than other progestins with regard to VTE risk.

Although these findings should be confirmed by randomized clinical trials, they strongly suggest that both the route of estrogen administration and the type of progestin may be important determinants of the overall benefit-risk profile of HT.


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Related medicine news :

1. ASTRO publishes evidence-based guideline for thoracic radiotherapy
2. Canadian Journal of Cardiology publishes advice on genetic testing of inherited cardiac arrhythmias
3. NYSCF - Robertson investigator publishes research to better understand pluripotent stem cells
4. ASTRO publishes palliative radiotherapy for bone metastases guideline
5. Practical Radiation Oncology publishes first issue
6. EMAS publishes position statements about the post-reproductive health of women
7. ASTRO publishes whole breast irradiation guidelines
8. ESMO publishes updated guidelines on cancer care
9. US Medical Supplies Publishes 2010 Catalog
10. AACR Adds to Growing STAR P-2 trial; Publishes Update and Perspectives in Cancer Prevention Research
11. Better Hearing Institute Publishes Comprehensive Consumer Guide to Buying Hearing Aids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... generation. Yisrayl makes an astounding statement when he says that the entire Bible ... Bible details the current times so plainly that anyone should be able to see ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association ... programs at the annual Building Better Radiology Marketing Programs conference, held this ... Fort Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... offering. ... Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Menopause market? What are the unit prices ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Fibromyalgia ... offering. ... latest research Fibromyalgia Drugs Price Analysis and Strategies - 2016, provides ... The research answers the following questions: ... attributes? How are they positioned in the Global Fibromyalgia market? ...
Breaking Medicine Technology: